Diarrhea in Oncology

Marion Debus

Last update: 12.06.2019

Diarrhea is a very common and often difficult to treat problem in the context of oncology. It is typically associated with a weakened life organization in the intestinal tract, expressed in regeneration disorders of the intestinal mucosa due to chemotherapy, radiation therapy or after bone marrow transplantation (GvHD). Diarrhea also occurs with infections which are more common in the context of a weakened immune system.

Among the chemotherapies that most frequently cause diarrhea are irinotecan and 5-fluorouracil. The causes of diarrhea after chemotherapy are manifold: motility, secretion and resorption disorders may all play a role. Diarrhea is also very common with the tyrosine kinase inhibitors commonly used today, such as imatinib. 

(Other causes, such as short bowel syndrome or pancreatic insufficiency, which also occur frequently in oncological patients, will not be considered here.)

A special form is diarrhea after rectal resection, which is difficult to influence and which develops due to the lack of reservoir function, something that often restricts the patient’s social activities in the long term. High doses of loperamide are often required, in many cases also Tinctura opii.

An increasingly diminished intervention of the soul body is expressed in accelerated intestinal passage and hypersecretion, which are often also accompanied by painful tenesmus in cases of physical damage (e.g., mucositis). The soul body no longer has a proper formative effect in the area of the weakened life organization and subsequently does not reach the physical level adequately either. There is a disturbance in the breathing equilibrium between the upbuilding resorption processes and the degenerative processes of secretion and movement.

The therapeutic approach

The therapeutic aim is to support upbuilding life processes and strengthen the structuring forces of the soul body in the area of the intestinal mucosa. The ‘I’-organization should be called upon to integrate and harmonize the exaggerated activity of the soul body. 

 

Research news

Case series: Topical application of Viscum album extract in keratinocyte carcinomas shows remissions 
A retrospective case series examined the safety and clinical effects of topical application of 10% lipophilic Viscum album extract (VALE) in individual cases of cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and actinic keratosis (AK). The study population consisted of 55 patients with 74 skin lesions. Risk factors, concomitant therapies and diseases, adverse drug reactions to VALE and other relevant information were documented. As a result, the clinical response rate was 78% for cSCC, 70% for BCC and 71% for AK. The complete remission rates for individual lesions were 56% for cSCC, 35% for BCC and 15% for AK. Overall, the results suggest that VALE is a safe and tolerable extract, and complete and partial remissions of ceratinocyte carcinomas were observed with its use. The article is published in Complementary Medicine Research
https://doi.org/10.1159/000537979.


Further information on Anthroposophic Medicine